Related Experiment Video
Updated: Sep 4, 2025
08:49
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
9.5K
Technology and technique for left ventricular assist device optimization: A Bi-Tech solution
Vincenzo Tarzia1, Matteo Ponzoni1, Gabriele Di Giammarco2
1Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Artificial Organs
|July 22, 2022
Summary
The Jarvik 2000 heart pump with a cone-bearing design and minimally invasive surgery significantly improved survival rates for LVAD patients. This combined approach also reduced the risk of cardiovascular events, enhancing patient outcomes.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
- Medical Devices
Background:
- Investigated the synergistic effect of the Jarvik 2000 cone-bearing design and minimally invasive surgery on Left Ventricular Assist Device (LVAD) patient outcomes.
- Evaluated the impact of technological advancements in LVADs on patient survival and adverse event rates.
Purpose of the Study:
- To assess the combined benefits of the Jarvik 2000's cone-bearing design and minimally invasive implantation techniques.
- To compare outcomes across different LVAD configurations and surgical approaches.
Main Methods:
- Retrospective review of 150 adult end-stage heart failure patients from the Jarvik 2000 Italian Registry (October 2008-October 2016).
- Patients categorized into three groups: pin-bearing/conventional, cone-bearing/conventional, and cone-bearing/minimally invasive.
- Analysis of discharge rates, transplantation, LVAD explantation, survival rates, and adverse event incidence.
Main Results:
- Overall 1-year survival rates were 58% (Group 1), 64% (Group 2), and 74% (Group 3), with a statistically significant difference (p=0.034).
- The cone-bearing design with minimally invasive surgery (Group 3) showed a significantly lower cumulative incidence rate for adverse events (22.1 per 100 patient-years) compared to the pin-bearing design (p=0.046).
- Discharge rates were comparable across groups (73%, 69%, 72%), but long-term survival and safety were notably improved in Group 3.
Conclusions:
- The combination of the Jarvik 2000's cone-bearing design and minimally invasive surgery significantly enhances survival and reduces cardiovascular event risk in LVAD patients.
- Integrating advanced LVAD technology with refined surgical techniques offers a superior approach for managing end-stage heart failure.
- This study highlights the importance of optimizing both device design and surgical methodology for improved LVAD therapy outcomes.
More Related Videos
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
01:22Heart Failure VI: Adjunct Therapies
25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
01:30Cardiomyopathy II: Dilated Cardiomyopathy
20
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
20